Chromomycin-A Large bowel 27 0 Moertel et al. 1975b 5-f1uorouracil (Moertel 1975) . Recent series reporting response rates of only 12% (Giles et al. 1974 ) and 9.5% (Cedermark et al. 1976 ) in colorectal cancer have been less encouraging and have shown that, in common with the other n~trosoureas, MeCCNU has the major side effect of delayed bone marrow toxicity. The ni tro~ureas have rapidly become established in the management ofgut cancer in America. In Britain the evaluation is proceeding more cautiously, and their place is far from certain. The results of initial assessments of other new drugs are shown in Table 2 . These figures are generally disappointing, but adriamycin in stomach cancer and ICRF 159 in rectal cancer may prove of some value.
Combination chemotherapy
In gut cancer combination cytotoxic therapy is in its infancy, but there are a few results available. A randomized study in gastric carcinoma has shown the combination of BCNU and 5-fluorouracil to be superior to 5-fluoY.:>uracil alone (Moertel 1975) and an Eastern Cooperative Oncology Group study with MeCCNU and 5-f1uorouracil claimed a 52% response rate (Moertel 1975) . A similar study in the UK, using the same two agents, has produced only a 7% response (R Kingston 1976, personal communication) . Results in largebowel cancer are summarized in Table 3 . The series reported by Falkson et al. (1974) and by Moertel, Schutt, Hahn, Marciniak & Reitemeier (1975) were both prospective studies which showed the combination to be more effective than 5-fluorouracil alone. In advanced bowel cancer one of two clinical problemf%is encountered: pelvic recurrence or blood-borne metastases. Cytotoxic drug therapy is otlittle benefit in pelvic recurrence, and radiotherapy is to be preferred; but for patients with liver or lung secondaries chemotherapy can be rewarding, as the series of 16 patients with predominant hepatic metastases demonstrates (Priestman 1973) . In pancreatic cancer there has -been a report of increased survival in patients with advanced disease treated by cytotoxics ). The numbers were small, but this was a prospective study and survival was significantly prolonged compared with untreated controls. Bleomycin and 5·fluorouracil are both said to have radiosensitizing effects in addition to their cytotoxic activity. Response rates of 62% (Kolaric et al. 1976 ) to 100% (Okamoto 1971 ) have been claimed, using the combination of bleomycin and radiotherapy in squamous cell carcinoma of the oesophagus. These were uncontrolled studies, however, and the preliminary results of a prospective trial from Cardiff have shown no benefit from adding bleomycin to radiation therapy (Priestman 1977a ). The role of 5-fluorouracil is more promising. Moertel et al. (1969) demonstrated significantly prolonged survival in patients with advanced pancreatic and gastric cancer when 5·fluorouracil was added to radiotherapy. Furthermore, Arnott (1975) has shown that the duration and dose of radiation required for palliation in advanced rectal cancer may be significantly reduced by the addition of 5·fluorouracil.
Adjuvant chemotherapy
A number of studies have reported recently on the value of long-term 5-fluorouracil administration as an adjuvant after resection of rectal carcinoma in the hope of reducing the incidence of recurrence or metastasis. Three trials have suggested that 5-fluorouracil is of value (Li & Ross 1976 , Mackman et al. 1974 , Mavligit et al. 1976 ), but all have relied on historical controls. The two studies showing no benefit (Grage et al. 1975 , Lawrence et al. 1975 were, however, prospective randomized series. The value of 5-fluorouracil as an adjuvant in rectal cancer is doubtful, and it has been argued that the next step, which is already being taken in America, should be trials using a combination of drugs. When there is no regimen of established value, to start such trials appears premature; moreover, by relying on cytotoxic treatment these patients may be missing the opportunity for adjuvant radiotherapy. There is increasing evidence that radiotherapy given at the time of resection helps to reduce the incidence of pelvic recurrence (Priestman 1977b) . A number of multicentre trials are under way to establish whether such treatment is best given pre-or post-operatively, and what the optimum radiation dose is.
A number of studies in gastric cancer have employed single-agent short-term adjuvant chemotherapy after gastrectomy, but none have shown any real benefit. A controlled study reported by Rake et al. (1976) has suggested, however, that prolonged chemotherapy may improve results after gastrectomy. Although the numbers in this study were small, it has prompted the establishment of a multicentre trial of long-term cytotoxic therapy in operable gastric cancer; the results from this work will be eagerly awaited.
Conclusion
Interest in chemotherapy of gastrointestinal cancer is slowly increasing, but one of the major obstacles to progress is the great pessimism that is felt generally about these cancers. Certainly there have not been any major breakthroughs comparable to those seen in Hodgkin's disease or childhood cancer in recent years. But there have been a number of encouraging developments which, if incorporated into a systematic plan of sequential controlled clinical trials, may well demonstrate improvements in remission rates and survival figures which will help to relieve the gloom.
[For a comprehensive list of references, see Priestman (1976) .]
